Truist on Insmed (INSM): Brinsupri Launch Outpacing Most Bullish Expectations
Tweet Send to a Friend
Truist Securities analyst Danielle Brill reiterated a Buy rating and $205.00 price target on Insmed (NASDAQ: INSM).The analyst commented: "Quick ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
